A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
← catalyst calendarNCT07013474 · readout in 404 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
300estimated
Sites
151
Countries
Argentina, Belgium, Brazil +15
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-14 | actual | When the study began enrolling |
| Primary completion | 2027-09-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-25 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COVID-19 Infection
Interventions
- Drug: ibuzatrelvir
- Drug: remdesivir — also filed as veklury
- Drug: placebo for ibuzatrelvir
- Drug: placebo for remdesivir
Primary outcome
what the primary-completion date above is the date OFThe difference in the proportion of patients meeting the primary composite endpoint, between ibuzatrelvir and remdesivir vs remdesivir groups in symptomatic adult participants with COVID-19 who are severely immunocompromised
measured 38 days
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed